AVNS
AVANOS MEDICAL, INC.Price
Daily candles with volume.
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells since Mar 6. Recent filings are awards, exercises and tax withholding.
- InstitutionsBEARISH
Q3 2026: 0 added (0 new), 16 trimmed or exited.
- EstimatesFALLING
Current-quarter EPS estimate $0.240 → $0.160 over 90 days. 0 up, 1 down in 30 days.
- Short sellersSTEADY
Short interest −1.3% to 1.75M shares. 2.4 days to cover, ≈3.7% of shares.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| MORGAN STANLEY | EXIT | $0.00 |
| BlackRock, Inc. | EXIT | $0.00 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | EXIT | $0.00 |
| VANGUARD CAPITAL MANAGEMENT LLC | EXIT | $0.00 |
| Qube Research & Technologies Ltd | EXIT | $0.00 |
| JPMORGAN CHASE & CO | EXIT | $0.00 |
| STATE STREET CORP | EXIT | $0.00 |
| FIL Ltd | EXIT | $0.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action May 2024| Date | Firm | Rating |
|---|---|---|
| May 7, 2024 | JMP Securities REITERATE | Market Perform |
| Jul 25, 2023 | Keybanc DOWNGRADE | Sector Weight |
| Jun 21, 2023 | Stifel REITERATE | Hold |
| May 22, 2023 | CL King INITIATE | Buy |
| May 4, 2023 | Morgan Stanley MAINTAIN | Underweight |
| Feb 22, 2023 | Morgan Stanley MAINTAIN | Underweight |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Galovan Scott Michael SVP, Chief Financial Officer Jul 27, 2026 | AWARD | 96,121 sh |
Delgado Sigfrido SVP, Operations Jul 27, 2026 | AWARD | 54,886 sh |
Galovan Scott Michael SVP, Chief Financial Officer Jul 27, 2026 | TO ISSUER | $2.4M |
Delgado Sigfrido SVP, Operations Jul 27, 2026 | TO ISSUER | $1.4M |
Galovan Scott Michael SVP, Chief Financial Officer Jul 27, 2026 | TO ISSUER | 69,630 sh |
Delgado Sigfrido SVP, Operations Jul 27, 2026 | TO ISSUER | 37,520 sh |
Galovan Scott Michael SVP, Chief Financial Officer Jul 27, 2026 | TO ISSUER | 21,038 sh |
Delgado Sigfrido SVP, Operations Jul 27, 2026 | TO ISSUER | 21,914 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Next Q | $0.33 | $0.33–$0.33 | +0.0% | $181.0M |
| Current FY | $1.00 | $1.00–$1.00 | +0.0% | $710.0M |
| Next FY | $1.25 | $1.25–$1.25 | +0.0% | $740.0M |
| Current Q | $0.16 | $0.16–$0.16 | +0.0% | $173.0M |
Washington
Short side
FINRA· Jul 15, 2026SecBot reports
7 filings · 3 bullish · 0 bearish · 4 neutral- NEUTRAL 25-NSEJul 27, 2026
The New York Stock Exchange filed a Form 25-NSE to delist Avanos Medical, Inc. (AVNS) following…
The merger is complete and the stock is delisted; no further trading in AVNS will occur. Shareholders who have not yet tendered should contact their broker regarding receipt of the $25.00 cash…
- BULLISH 8-K, DEFA14AJul 2, 2026
Avanos Medical received all required regulatory approvals for its pending acquisition by American…
The stock should re-rate closer to the deal price as the special meeting approaches. Monitor for any dissident stockholder opposition or competing bids, but the regulatory milestone makes deal…
- BULLISH DEFM14AJun 10, 2026
Avanos Medical enters a definitive agreement to be acquired by American Industrial Partners (AIP)…
Traders should note the stock has already converged to near the $25.00 deal price (closed at $25.00 on June 8, 2026), indicating minimal arbitrage spread. The primary risk is deal completion, focus…
- NEUTRAL DEFA14AMay 5, 2026
Avanos Medical filed additional definitive proxy soliciting materials (DEFA14A) related to its…
The filing confirms deal momentum and strong Q1 performance, but provides no new financial details or regulatory updates. Traders should watch for the definitive proxy statement filing and any…
All AVNS filing & press-release reports (7)
- 25-NSE reportJul 27, 2026
- 8-K, DEFA14A reportJul 2, 2026
- DEFM14A reportJun 10, 2026
- DEFA14A reportMay 5, 2026
- DEFA14A reportApr 23, 2026
- DEFA14A reportApr 14, 2026
- 8-K reportFeb 26, 2026